Please login to the form below

Not currently logged in
Email:
Password:

Penn Pharma appoints new CEO

Penn Pharma has announced the appointment of a new chief executive officer, Richard Yarwood

Penn Pharma has announced the appointment of a new chief executive officer, Richard Yarwood. He joins the company with more than 33 years experience in the pharmaceutical industry. He will manage the south Wales headquartered business as expands and strengthens its services and international presence.

 

Richard Yarwood
Richard Yarwood

 

Yarwood joins the 245-strong team at Penn Pharma to oversee its importation and distribution of clinical trial and commercial material for clients in the UK and internationally. He said: "Penn Pharma is a highly reputable business with a team of experienced and ambitious professionals who have succeeded in building an impressive international presence. 

"I am confident that I will be able to work competently with the team to further strengthen the business's market presence and to ensure that Penn Pharma remains a well-known and well-respected name worldwide."

Yarwood is a pharmacy graduate from Nottingham University. He gained a PhD from Manchester University and an MBA from Warwick University before going onto pursue a successful career in the pharmaceutical industry. He has held senior positions including group president of Sterile Technologies at Catalent Pharma Solutions and president for Europe and Asia Pacific at Catalent.

Penn has also appointed a new operations director, David Cooper, to its senior team. Previously general manager of oral technologies at Zydis, David brings with him extensive experience in global manufacturing, gained from Mylan Pharmaceuticals, formerly Merck Generics. David will be responsible for overseeing operations from Penn Pharma's single-site facility in south Wales. 

Mark Molyneux, chairman at Penn Pharmaceutical Services, said: "These are two key appointments for us at Penn Pharma. Both Richard and David will be valuable additions to our board of directors, and their appointments mark another important step as the company rolls out a £12m expansion programme over the next five years."

30th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics